THERE are calls to prioritise vulnerable regional, rural and remote Australians for the Pfizer/BioNTech COVID-19 vaccine, which was approved for use by the Therapeutic Goods Administration (TGA) on Monday.
The National Rural Health CEO Gabrielle O’Kane said people in rural, regional and remote communities experienced poorer health outcomes than those in major cities, which put them in a higher ...
